Syngene International SYNGENE
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Syngene International's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
AI analysis and Advanced tools for SYNGENE
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 7,054.7 | 6,795.9 | 6,151.6 |
| Accumulated Depreciation Total | -2,782.3 | -2,402.8 | -2,086.5 |
| Cash Equivalents | 28 | 85.5 | Not available |
| Other Liabilities Total | 264.8 | 263.9 | 284.5 |
| Accrued Expenses | 26.3 | 0.3 | Not available |
| Common Stock Total | 402.9 | 402.5 | 402 |
| Other Equity Total | -101.5 | 94.6 | 109.2 |
| Other Current Assets Total | 6.9 | 53.2 | 69.4 |
| Prepaid Expenses | 37 | 25.8 | 16.4 |
| Total Assets | 7,054.7 | 6,795.9 | 6,151.6 |
| Current Portof LT Debt/Capital Leases | 50.5 | 152 | 90.1 |
| Additional Paid-In Capital | 270.6 | 243.7 | 216.7 |
| Cash | 200.6 | 281.6 | 85.7 |
| Total Equity | 4,839.1 | 4,726.8 | 4,257.8 |
| Long Term Investments | 591.9 | 72.3 | 76 |
| Retained Earnings(Accumulated Deficit) | 4,272.4 | 3,991.3 | 3,535.2 |
| Treasury Stock-Common | -5.3 | -5.3 | -5.3 |
| Total Common Shares Outstanding | 40.18 | 40.14 | 40.08 |
| Property/Plant/Equipment Total-Gross | 6,752.8 | 6,406 | 5,703.9 |
| Tangible Book Valueper Share Common Eq | 119.35 | 117 | 105.5 |
| Total Liabilities | 2,215.6 | 2,069.1 | 1,893.8 |
| Total Debt | 458.4 | 577.9 | 555.2 |
| Short Term Investments | 1,060.5 | 1,030.4 | 991 |
| Cashand Short Term Investments | 1,289.1 | 1,397.5 | 1,076.7 |
| Total Receivables Net | 668.5 | 655.3 | 558 |
| Notes Payable/Short Term Debt | 9.4 | 17.1 | 0 |
| Accounts Receivable-Trade Net | 531 | 540.6 | 458.2 |
| Property/Plant/Equipment Total-Net | 3,970.3 | 4,003.2 | 3,617.5 |
| Total Current Liabilities | 1,552.3 | 1,396.4 | 1,144.2 |
| Total Inventory | 141.3 | 155.5 | 238.5 |
| Accounts Payable | 347.5 | 352 | 255.5 |
| Other Currentliabilities Total | 1,118.6 | 875 | 798.6 |
| Total Long Term Debt | 398.5 | 408.8 | 465.1 |
| Intangibles Net | 43.9 | 30.3 | 29.5 |
| Other Long Term Assets Total | 172.7 | 250 | 268.2 |
| Note Receivable-Long Term | 133.1 | 152.8 | 201.4 |
| Total Current Assets | 2,142.8 | 2,287.3 | 1,959 |
| Capital Lease Obligations | 398.5 | 408.8 | 365.1 |
| Long Term Debt | Not available | 0 | 100 |
Valuation and ratios
Growth
Debt 5Yr CAGR %-12.48
Margins
Operating Margin 12m10.14
Operating Margin 5y Avg16.51
Net Profit Margin 12m6.14
Net Profit Margin 5y13.1
Yield
Dividend Yield %0.31
Valuation
Price to Sale Ratio4.30
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk34.99
Analyst consensus
ConsensusBuy
Consensus score2.38
Analyst opinions8
Strong Sell count1
Sell count0
Hold count2
Buy count3
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Ownership
- Promoter
- 52.59%
- FII
- 11.82%
- MF
- 25.78%
- Other
- 9.81%
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Buy or sell stocks for 16 March: Vaishali Parekh recommends two intraday stocks to buy today — Syngene International, Tata Consumer Products
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Syngene International, Muthoot Finance, and Tata Consumer Products
Buy or sell: Vaishali Parekh recommends three intraday stocks to buy today — Syngene International, Carborundum Universal, and Hyundai Motor India
Mirae Asset Mutual Fund has slightly decreased its stake in Syngene International to 2.95% by selling 667,386 shares. Syngene, which reported a 59% rise in Q1 FY26 profit, remains under stock pressure despite a significant long-term gain since March 2020.
Stock Market Today: Syngene International share price gained more than 2% in the intraday trades on Friday despite weak Indian stock markets. Should you buy or sell?
Technical Picks: Nagaraj Shetti of HDFC Securities recommends these two stocks this week - Crisil Ltd, and Syngene International Ltd.
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2500 per share(12.5%)Final Dividend
- annual General MeetingPOM
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- annual General MeetingPOM
- dividendRs.1.2500 per share(12.5%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2500 per share(12.5%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Discussion and sentiment for Syngene International
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Community discussion loads as you approach this section.
Business information
What the company does
Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics. It has capabilities for current Good Manufacturing Practices (cGMP) manufacturing from benchtop volume to commercial scale. SynVent is its drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SYNGENE
- BSE Code
- 539268
Stock FAQ
What is the symbol and ISIN of Syngene International?
Syngene International has the symbol SYNGENE and ISIN - INE398R01022.
What is the latest recorded price of Syngene International?
The latest available recorded price of Syngene International is INR 399.75 as of 2026-08-06T20:55:05.286Z. This is a source-stamped snapshot, not a live quote.
What are the year high and year low of Syngene International?
Year high: INR 709.30. Year low: INR 375.50.
What is the market capitalization of Syngene International?
Market capitalization: INR 16,091.36 crore.
What is the P/E ratio of Syngene International?
P/E ratio: 79.96.
What is the dividend yield of Syngene International?
Dividend yield: 0.31%.
How is the financial performance of Syngene International based on revenue, net income, and EPS?
Revenue: INR 3,738.70 crore. Net income: INR 316.70 crore. EPS: INR 6.74.
What are the price-to-book and price-to-sales ratios of Syngene International?
Price-to-book ratio is unavailable in the current source. Price-to-sales ratio: 4.30.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.